Using Digital Tools to Advance Alzheimer's Drug Trials During a Pandemic: The EU/US CTAD Task Force
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The 2020 COVID-19 pandemic has disrupted Alzheimer's disease (AD) clinical studies worldwide. Digital technologies may help minimize disruptions by enabling remote assessment of subtle cognitive and functional changes over the course of the disease. The EU/US Clinical Trials in Alzheimer's Disease (CTAD) Task Force met virtually in November 2020 to explore the opportunities and challenges associated with the use of digital technologies in AD clinical research. While recognizing the potential of digital tools to accelerate clinical trials, improve the engagement of diverse populations, capture clinically meaningful data, and lower costs, questions remain regarding the stability, validity, generalizability, and reproducibility of digital data. Substantial concerns also exist regarding regulatory acceptance and privacy. Nonetheless, the Task Force supported further exploration of digital technologies through collaboration and data sharing, noting the need for standardization of digital readouts. They also concluded that while it may be premature to employ remote assessments for trials of novel experimental medications, remote studies of non-invasive, multi-domain approaches may be feasible at this time.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The World report on ageing and health: a policy framework for healthy ageing
Beard, J. R., Officer, A., de Carvalho, I. A., Sadana, R., Pot, A. M., Michel, J.-P., Lloyd-Sherlock, P., Epping-Jordan, J. E., Peeters, G. M. E. E. (., Mahanani, W. R., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00516-4 · Cited by 3,287
Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: The PACC5
Papp, K. V., Rentz, D. M., Orlovsky, I., Sperling, R. A., & Mormino, E. C. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.10.004 · Cited by 303
Self-citationImpact of COVID-19 on clinical trials and clinical research: A systematic review
Sathian, B., Asim, M., Banerjee, I., Pizarro, A. B., Roy, B., Van Teijlingen, E. R., Nascimento, I. J. B. D., & Alhamad, H. K. (2020) · Nepal Journal of Epidemiology · doi:10.3126/nje.v10i3.31622 · Cited by 242
Beattie, Z., Miller, L. M., Almirola, C., Au-Yeung, W.-T. M., Bernard, H., Cosgrove, K. E., Dodge, H. H., Gamboa, C. J., Golonka, O., Gothard, S., et al. (2020) · Digital Biomarkers · doi:10.1159/000512208 · Cited by 71
Self-citation
Cited by
Towards a future where Alzheimer’s disease pathology is stopped before the onset of dementia
van der Flier, W. M., de Vugt, M. E., Smets, E. M. A., Blom, M., & Teunissen, C. E. (2023) · Nature Aging · doi:10.1038/s43587-023-00404-2 · Cited by 220
Polk, S. E., Öhman, F., Hassenstab, J., König, A., Papp, K. V., Schöll, M., & Berron, D. (2025) · npj Digital Medicine · doi:10.1038/s41746-025-01583-5 · Cited by 73
Self-citationAutomated detection of progressive speech changes in early Alzheimer's disease
Robin, J., Xu, M., Balagopalan, A., Novikova, J., Kahn, L., Oday, A., Hejrati, M., Hashemifar, S., Negahdar, M., Simpson, W., et al. (2023) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12445 · Cited by 21
Metadata
- Authors
- Kaye, J., Aisen, P., Amariglio, R., Au, R., Ballard, C., Carrillo, M., Fillit, H., Iwatsubo, T., Jimenez-Maggiora, G., Lovestone, S., Natanegara, F., Papp, K., Soto, M. E., Weiner, M., & Vellas, B.
- Venue
- The Journal of Prevention of Alzheimer's Disease
- Publisher
- Elsevier BV
- Published
- 2021-10
- Volume
- 8
- Issue
- 4
- Pages
- 513-519
- ISSN
- 2274-5807 (ISSN-L)
- OpenAlex
- W3174645852
- Cited by
- 41
- References
- 4
- FWCI
- 5.71
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.